Physician
Raymonville Pediatrics
Raymonville Pediatrics was paid $8.49M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoRAYMONVILLE PEDIATRICS
RAYMONDVILLE, TX 78580
RAYMONDVILLE, TX 78580
33aNPI1588847107assigned 12/06/2007
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$8.49M
24GClaims396,392
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Texas
Rank by total paid#1 of 21
Median peer was paid$446K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 326 | $10K | |
| 2019 | 534 | $16K | |
| 2020 | 11,756 | $221K | |
| 2021 | 69,391 | $1.45M | |
| 2022 | 97,272 | $2.09M | |
| 2023 | 106,123 | $2.33M | |
| 2024incomplete | 110,990 | $2.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 81,208 | 58,279 | $2.83M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 17% | 36,480 | 31,169 | $1.40M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 11% | 68,525 | 29,467 | $913K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 7.2% | 45,628 | 38,491 | $610K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.7% | 5,550 | 5,391 | $400K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.6% | 5,149 | 5,007 | $389K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 3,923 | 3,770 | $306K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.1% | 11,394 | 10,078 | $263K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.7% | 3,188 | 3,036 | $225K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 2,320 | 2,197 | $113K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.2% | 11,071 | 4,444 | $104K |
| S8301 | Infection control supplies, not otherwise specified | 1.0% | 4,297 | 3,718 | $87K |
85 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 9,498 | $75K |
| 31000 | <1% | 614 | $62K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,373 | $53K |
| 99381 | <1% | 721 | $51K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,190 | $39K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 891 | $39K |
| 99000 | <1% | 4,223 | $39K | |
| 86580 | <1% | 5,044 | $38K | |
| 99429 | <1% | 1,153 | $37K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,826 | $36K |
| 99383 | <1% | 358 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,200 | $26K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,768 | $26K |
| 99382 | <1% | 291 | $25K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 328 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 639 | $20K |
| 85027 | <1% | 3,849 | $19K | |
| 99051 | <1% | 4,368 | $19K | |
| 90461 | <1% | 2,338 | $17K | |
| 74018 | <1% | 621 | $15K | |
| 83655 | <1% | 1,458 | $14K | |
| 92588 | <1% | 513 | $13K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 452 | $12K |
| 81002 | <1% | 4,136 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 192 | $11K |
| 99384 | <1% | 101 | $9K | |
| 86318 | <1% | 526 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 699 | $8K |
| 96160 | <1% | 4,756 | $7K | |
| 92567 | <1% | 569 | $7K | |
| 29515 | <1% | 145 | $7K | |
| 81025 | <1% | 704 | $5K | |
| 73120 | <1% | 206 | $5K | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 299 | $3K |
| 0001A | <1% | 78 | $3K | |
| 87561 | <1% | 71 | $3K | |
| 0071A | <1% | 85 | $3K | |
| 73600 | <1% | 114 | $3K | |
| 0002A | <1% | 60 | $2K | |
| 86308 | <1% | 511 | $2K | |
| 97170 | <1% | 55 | $2K | |
| 99001 | <1% | 892 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21 | $2K |
| 0072A | <1% | 44 | $2K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 176 | $2K |
| 81003 | <1% | 819 | $1K | |
| G0271 | Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes | <1% | 12,997 | $1K |
| 86328 | <1% | 40 | $1K | |
| 81000 | <1% | 391 | $1K | |
| 29125 | <1% | 15 | $742.70 | |
| 82947 | <1% | 218 | $696.96 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 16 | $674.36 |
| 96161 | <1% | 1,905 | $593.19 | |
| 73620 | <1% | 26 | $505.00 | |
| 90473 | <1% | 142 | $288.75 | |
| 69210 | <1% | 13 | $273.07 | |
| 81007 | <1% | 74 | $251.80 | |
| 99050 | <1% | 15 | $224.10 | |
| 97802 | <1% | 1,353 | $90.94 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 112 | $34.20 |
| G9716 | Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason | <1% | 57 | $23.93 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 247 | $4.31 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $1.45 |
| 90651 | <1% | 1,193 | $0.69 | |
| 90620 | <1% | 344 | $0.49 | |
| 90686 | <1% | 763 | $0.43 | |
| S9451 | Exercise classes, non-physician provider, per session | <1% | 13,072 | $0.01 |
| 90680 | 0% | 1,609 | $0.00 | |
| 90716 | 0% | 581 | $0.00 | |
| 90723 | 0% | 848 | $0.00 | |
| 90696 | 0% | 430 | $0.00 | |
| 91307 | 0% | 143 | $0.00 | |
| 90697 | 0% | 1,082 | $0.00 | |
| 90656 | 0% | 52 | $0.00 | |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | 0% | 31 | $0.00 |
| 96127 | 0% | 14 | $0.00 | |
| 90734 | 0% | 1,090 | $0.00 | |
| 90670 | 0% | 2,624 | $0.00 | |
| 90710 | 0% | 669 | $0.00 | |
| 90648 | 0% | 1,402 | $0.00 | |
| 90707 | 0% | 594 | $0.00 | |
| 90700 | 0% | 510 | $0.00 | |
| 90715 | 0% | 466 | $0.00 | |
| 90633 | 0% | 1,377 | $0.00 | |
| 91300 | 0% | 156 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREY, ROBERTO (MANAGER)